Phaseline

Targets › GGPS1

GGPS1 (Geranylgeranyl pyrophosphate synthase): drug programs, companies and trials

2 programs from 2 companies in 2 trials: 1 Phase 2, 1 Phase 4; Oncology, Gastroenterology; next expected readout Dec 2026.

Catalyzes the trans-addition of the three molecules of IPP onto DMAPP to form geranylgeranyl pyrophosphate, an important precursor of carotenoids and geranylated proteins. (UniProt, O95749)

Open in Phaseline: the race on GGPS1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Bahria Universityalendronate sodium powder
Bisphosphonate; inhibits farnesyl pyrophosphate synthase, blocking osteoclast bone resorpt
GGPS1Phase 4Alveolar Bone Loss Associated Chronic PeriodontitisSep 2027
Second Affiliated Hospital, Zhejiang University, School of MedicineZoledronic Acid-loaded Bone Cement
Farnesyl pyrophosphate synthase inhibitor; bisphosphonate that inhibits osteoclast functio
GGPS1Phase 2Giant Cell Tumor of BoneDec 2026

Conditions

Giant Cell Tumor of Bone (1) Alveolar Bone Loss Associated Chronic Periodontitis (1)

Modalities

small molecule (1)

Companies

Second Affiliated Hospital, Zhejiang University, School of Medicine (1) Bahria University (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.